Інформація призначена тільки для фахівців сфери охорони здоров'я, осіб,
які мають вищу або середню спеціальну медичну освіту.

Підтвердіть, що Ви є фахівцем у сфері охорони здоров'я.

International journal of endocrinology 5 (45) 2012

Back to issue

Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy

Authors: Campbell C.M., Kipnes M.S., Stouch B.C. et al.

Categories: Endocrinology

Sections: Specialist manual

print version

A length-dependent neuropathy with pain in the feet is a common complication of diabetes (painful diabetic neuropathy). It was hypothesized that pain may arise from sensitized-hyperactive cutaneous nociceptors, and that this abnormal signaling may be reduced by topical administration of the a(2)-adrenergic agonist, clonidine, to the painful area. This was a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. Nociceptor function was measured by determining the painfulness of 0.1% topical capsaicin applied to the pretibial area of each subject for 30 minutes during screening. Subjects were then randomized to receive 0.1% topical clonidine gel (n = 89) or placebo gel (n = 90) applied 3 times a day to their feet for 12 weeks. The difference in foot pain at week 12 in relation to baseline, rated on a 0–10 numerical pain rating scale (NPRS), was compared between groups. Baseline NPRS was imputed for missing data for subjects who terminated the study early. The subjects treated with clonidine showed a trend toward decreased foot pain compared to the placebo-treated group (the primary endpoint; P = 0.07). In subjects who felt any level of pain to capsaicin, clonidine was superior to placebo (P < 0.05). In subjects with a capsaicin pain rating ≥ 2 (0–10, NPRS), the mean decrease in foot pain was 2.6 for active compared to 1.4 for placebo (P = 0.01). Topical clonidine gel significantly reduces the level of foot pain in painful diabetic neuropathy subjects with functional (and possibly sensitized) nociceptors in the affected skin as revealed by testing with topical capsaicin. Screening for cutaneous nociceptor function may help distinguish candidates for topical therapy for neuropathic pain.

Pain. — June 2012


Similar articles

Correlation between type 2 diabetes mellitus and ankle-brachial index in a geographically specific Greek population without peripheral arterial disease
Authors: Koufopoulos G., Pafili K., Papanas N.
Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece

International journal of endocrinology Том 15, №7, 2019
Date: 2020.01.09
Categories: Endocrinology
Sections: Clinical researches
The potential role of benfotiamine in the treatment of diabetic cardiac autonomic neuropathy
Authors: V.A. Serhiyenko(1), V.B. Segin(2), L.M. Serhiyenko(1), A.A. Serhiyenko(1)
(1) — Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
(2) — Lviv Regional State Clinical Treatment and Diagnostic Endocrinology Center, Lviv, Ukraine

International journal of endocrinology Том 16, №3, 2020
Date: 2020.07.09
Categories: Endocrinology
Sections: Specialist manual
Transketolase activators as a novel therapy: their significance in the pathogenesis and treatment of diabetic microvascular complications
Authors: Singh K., Yuzvenko T., Kogut D.
Ukrainian Research and Practical Centre for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine

International journal of endocrinology Том 15, №7, 2019
Date: 2020.01.09
Categories: Endocrinology
Sections: Specialist manual

Back to issue